Cannabinoid Receptor

Receptor

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Related Products (380)
Antibodies (1)
Cannabinoid Receptor Isoform Comparison

By Effects:	Controls (2) Inhibitors (31) Ligands (8) Agonists (112) Antagonists (61) Activators (11) Modulators (20) Chemical (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-15443

AM251	Antagonist	99.09%
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM.

HY-10863

Anandamide	Agonist	≥99.0%
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.

HY-14136

Rimonabant	Antagonist	99.18%
Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a K_i of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-B0151

Pregnenolone	Inhibitor	99.87%
Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels.

HY-W011051

2-Arachidonoylglycerol	Agonist	99.09%
2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.

HY-100197

Synaptamide	Agonist	99.30%
Synaptamide (Dehydroepiandrosteron; DHEA) is an endogenous metabolite and structural analogue of Anandamide. Synaptamide binds to both the cannabinoid-1 and 2 (CB1 and CB2) cannabinoid receptors and has anti-inflammatory properties. Synaptamide is the first small-molecule endogenous ligand of an adhesion G protein-coupled receptor (aGPCR) .

HY-103335

O1918	Antagonist
O1918 is a selective non-CB₁ receptor and GPR18 antagonist.

HY-13439

SR144528	Antagonist	99.25%
SR144528 is a potent and selective CB2 receptor antagonist with a K_i of 0.6 nM.

HY-18697

JD-5037	Antagonist	99.38%
JD-5037 is a potent CB₁R antagonist with an IC₅₀ of 1.5 nM.

HY-14137

Rimonabant Hydrochloride	Antagonist	99.79%
Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-N1415

β-Caryophyllene	Agonist	99.55%
β-Caryophyllene is a CB2 receptor agonist.

HY-110004

ACEA	Agonist
ACEA (short for arachidonyl-2'-chloroacetamide) is a synthetic organic compound that acts as an agonist of the cannabinoid receptor CB1. It is a chemical that affects the endocannabinoid system in the body, which regulates various physiological processes such as appetite, pain perception, mood, and memory.

HY-110189

Pregnenolone monosulfate sodium	Inhibitor	99.96%
Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication. Pregnenolone monosulfate sodium is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels.

HY-W008364

Olivetol	Inhibitor	99.81%
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2. Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively.

HY-153800

Monlunabant	Antagonist	99.89%
Monlunabant ((S)-MRI-1891) is an orally active antagonist for cannabinoid receptor 1 (CB1), binds to hCB1 and hCB2 with K_i of 0.3 nM and 613 nM.

HY-10013

Taranabant	Inhibitor	99.06%
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

HY-W005629

Leelamine	Agonist	98.36%
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC₅₀ value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells.

HY-N0919

Yangonin	Inhibitor	99.79%
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-B1161A

S-Methoprene	Antagonist	98.58%
S-Methoprene is an insect juvenile hormone analog and effective insecticide that blocks the transition from pupa to adult. S-Methoprene is also a CB(1) receptor ligand and inhibits the binding of the CB1 receptor antagonist [³H]CP-55940 to the CB1 receptor (IC₅₀: 19.31 μM).

HY-113204

N-Oleoyl glycine	Activator	≥99.0%
N-Oleoyl glycine is a lipoamino acid, which stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.

Anandamide	CB1	CB2	≥99.0%
Rimonabant	CB1 , Ki: 1.8 nM		99.18%
Pregnenolone	CB1		99.87%
Synaptamide	CB1 , Ki: 633 nM	CB2 , Ki: 3843 nM	99.30%
SR144528		CB2	99.25%
JD-5037	CB1 , IC₅₀: 1.5 nM		99.38%
Rimonabant Hydrochloride	CB1 , Ki: 1.8 nM		99.79%
Pregnenolone monosulfate sodium	CB1		99.96%
Leelamine	CB1	CB2	98.36%
Yangonin	CB1 , IC₅₀: 1.79 μM CB1 , Ki: 0.72 μM		99.79%
N-Oleoyl glycine	CB1		≥99.0%
GW-405833	CB1 , EC₅₀: 16.1 μM	CB2 , EC₅₀: 50.7 nM	99.12%
Pregnenolone monosulfate	CB1		99.22%
AM281	CB1 , IC₅₀: 9.91 nM	CB2 , IC₅₀: 13000 nM	≥99.0%
Leelamine hydrochloride	CB1		99.06%
Etrinabdione		CB2	99.16%
CB2R PAM		cannabinoid type-2 receptors	98.46%
CB1 antagonist 4	CB1		99.00%
SCH 336		hCB2-R	98.85%
Tetrahydromagnolol	CB1 , EC₅₀: 9010 nM CB1 , Ki: 2260 nM	CB2 , EC₅₀: 170 nM CB2 , Ki: 416 nM	99.79%
Bay 59-3074	CB1 , Ki: 48.3 nM	CB2 , Ki: 45.5 nM	98.60%
CB1/2 agonist 3	hCB1-R, Ki: 5.9 nM	hCB2-R, Ki: 3.5 nM	99.83%
CB1/2 agonist 1	hCB1-R, EC₅₀: 56.15 nM	cannabinoid type-2 receptors, EC₅₀: 11.63 nM	99.20%
Drinabant	hCB1-R, IC₅₀: 25 nM rCB1-R, IC₅₀: 10 nM	CB2 , IC₅₀: 10000 nM	≥99.0%
AZD1940	hCB1-R, pKi: 7.93	hCB2-R, pKi: 9.06	99.58%
Pregnenolone (Standard)	CB1
GAT211	CB1		99.98%
Auriculasin	CB1 , IC₅₀: 8.92 μM		98.58%
Tedalinab		CB2	99.94%
(R)-Methanandamide	CB1 , Ki: 20 nM
CB2R antagonist 3		CB2R	98.08%
GW 833972A		hCB2-R, pEC₅₀: 7.3 rat CB2-R, pEC₅₀: 7.5	99.91%
Ibipinabant	CB1 , Ki: 7.8 nM	CB2 , Ki: 7943 nM	99.90%
CB2 modulator 1		CB2	99.75%
PGN36		cannabinoid type-2 receptors, Ki: 0.09 μM	99.74%
2-Palmitoylglycerol	CB1		≥99.0%
RVD-Hpα TFA	CB1		99.32%
ANEB-001	CB1
Noladin ether	CB1 , Ki: 21.2 nM	CB2 , Ki: >3 mM	≥98.0%
CB2R/FAAH modulator-3	CB1 , Ki: 67.6 nM	CB2 , Ki: 20.1 nM	99.71%
CB2 receptor agonist 2		CB2 , Ki: 8.5 nM	≥99.0%
Nonabine	CB1		99.95%
URB447	CB1 , IC₅₀: 313 nM		99.5%
L759633	CB1 , Ki: 1043 nM	CB2 , Ki: 6.4 nM	≥99.0%
N-Arachidonyldopamine	CB1 , Ki: 250 nM		98.36%
MJ15	rCB1-R, Ki: 27.2 pM rCB1-R, IC₅₀: 118.9 pM
PSNCBAM-1	hCB1-R, EC₅₀: 0.1 μM		99.48%
Zevaquenabant	CB1
AM9405	CB1 , IC₅₀: 45.71 nM
Isopropyl dodec-11-enylfluorophosphonate	CB1 , IC₅₀: 2 μM
(R)-SLV 319	CB1 , Ki: 894 nM
RTICBM-189	CB1 , pIC₅₀: 7.54 hCB₁, pIC₅₀: 5.29 mCB₁, pIC₅₀: 6.25		99.73%
CB2 receptor agonist 9		CB2R, EC₅₀: 16.2 nM
AChE/BChE-IN-18		CB2 , Ki: 31 nM
LY320135	CB1 , Ki: 141 nM	CB2 , Ki: >10 μM
Dihomo-γ-Linolenoyl Ethanolamide	hCB1-R, Ki: 857 nM	hCB2-R, Ki: 598 nM
O-2050	CB1 , Ki: 2.5 nM	CB2 , Ki: 0.2 nM
CB2 receptor agonist 8		CB2R
CB1R agonist 1	CB1R, Ki: 0.95 nM
Tocrifluor 1117	CB1
CB1R Allosteric modulator 4	hCB1-R
hBChE-IN-2		hCB2-R, IC₅₀: 0.78 μM
BAY 38-7271	CB1 , Ki: 1.85 nM	CB2 , Ki: 5.96 nM
CB2R-IN-1		CB2 , Ki: 0.9 nM
CB1R Allosteric modulator 3	CB1		98.05%
CB2R agonist 3		CB2R, EC₅₀: 0.37 μM
PSB-SB-1203	CB1 , Ki: 0.244 μM	CB2 , Ki: 0.21 μM
SMM-189		CB2
MDA7	rCB1-R, Ki: 2565 nM	rat CB2-R, IC₅₀: 67.4 nM hCB2-R, IC₅₀: 128 nM rat CB2-R, Ki: 238 nM hCB2-R, Ki: 422 nM
MN-25	CB1 , Ki: 254 nM	CB2 , Ki: 11 nM
CB1/2 receptor-1	CB1	CB2
CBR Agonist-2	hCB1-R, EC₅₀: 960 nM hCB1-R, Ki: 970 nM
CB2R probe 1		cannabinoid type-2 receptors, Ki: 130 nM
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide	CB1 , Ki: 21 μM	CB2 , Ki: 21 μM
CB2 receptor agonist 6		CB2R
CB2R/FAAH modulator-2	CB1 , Ki: 152.9 nM	CB2 , Ki: 10.8 nM
Docosatetraenylethanolamide	CB1
CB2R agonist 1		CB2R, EC₅₀: 0.56 μM
R-2 Methanandamide	rCB1-R, Ki: 119 nM
TRPV1/CB2 agonist 1		CB2
Amauromine	CB1 , Ki: 178 nM CB1 , Kb: 66.6 nM
CB1R antagonist 1	hCB1-R, IC₅₀: 4.2 μM hCB1-R, EC₅₀: 10 μM		99.89%
CB1 inverse agonist 2	CB1 , pKi: 9.7	CB2 , pKi: 6.0
rel-O-2050	CB1
CB2R/FAAH modulator-1	CB1R, Ki: 241.3 nM CB1R, EC₅₀: 489 nM	CB2R, Ki: 14.8 nM CB2R, EC₅₀: 123.6 nM
AZD-2207	CB1
CB1/2 agonist 2	hCB1-R, Ki: 3.5 nM	hCB2-R, Ki: 1.2 nM
CB1R Allosteric modulator 2	hCB1-R
CB1R Allosteric modulator 1	hCB1-R
Δ9-THCB	CB1 , Ki: 15 nM	CB2 , Ki: 51 nM
Mead ethanolamide	CB1 , Kd: 753 nM	CB2 , Kd: 1810 nM
PM226		CB2 , Ki: 13 nM CB2 , EC₅₀: 39 nM
NIDA-41020	CB1 , Ki: 4.1 nM
RVD-Hpα	CB1
CBR Agonist-1	rCB1-R, Ki: 0.18 μM	hCB2-R, Ki: 1.22 μM
AB-FUBICA	CB1 , EC₅₀: 21 nM	CB2 , EC₅₀: 15 nM
MRL-650	CB1 , IC₅₀: 7.5 nM	CB2 , IC₅₀: 4100 nM
Eicosapentaenoyl ethanolamide	CB1	CB2
CB1-IN-2	CB1 , IC₅₀: 0.644 μM
CB1 antagonist 5	hCB₁, EC₅₀: 195 nM hCB₁, Ki: 243 nM
Δ8-THC-C8	CB1 , EC₅₀: 13.8 nM
Δ8-THC methyl ether		CB2
PF-03550096		CB2 , Ki: 7.9 nM
TM38837	CB1
PSB-SB1202	CB1 , EC₅₀: 56 nM CB1 , Ki: 32 nM	CB2 , EC₅₀: 14 nM CB2 , Ki: 49 nM
Δ8-THCP	CB1

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Related Products (380)

Antibodies (1)

Cannabinoid Receptor Isoform Comparison

Cannabinoid Receptor Related Products (380):